GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment, despite having its own ADC in development.
This move fuels the industry buzz for the promising anti-tumour modality, with GSK doubling down on the modality.
The acquisition is valued at £268m.
The gold standard of business intelligence.
GSK's decision combines business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Author's summary: GSK buys Syndivia's ADC for £268m.